The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PBH | -20.48% | +53.37% | +8.92% | +277% |
| S&P | +12.9% | +73.65% | +11.66% | +471% |
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.
These stocks helped pull down the entire stock market.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $283.44M | -2.4% |
| Gross Profit | $152.22M | -2.5% |
| Gross Margin | 53.70% | -0.1% |
| Market Cap | $2.97B | -23.1% |
| Market Cap / Employee | $4.94M | 0.0% |
| Employees | 600 | 5.3% |
| Net Income | $46.70M | -23.5% |
| EBITDA | $90.08M | -8.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $62.37M | 22.6% |
| Accounts Receivable | $190.46M | 13.9% |
| Inventory | 163.6 | 8.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.07B | 4.9% |
| Short Term Debt | $8.63M | 24.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.47% | -0.9% |
| Return On Invested Capital | 4.90% | 0.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $75.26M | 18.5% |
| Operating Free Cash Flow | $78.29M | 20.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 20.06 | 18.73 | 15.48 | 16.31 | -10.85% |
| Price to Book | 2.38 | 2.15 | 1.66 | 1.63 | -27.09% |
| Price to Sales | 3.78 | 3.55 | 2.77 | 2.69 | -23.01% |
| Price to Tangible Book Value | -4.06 | -4.00 | -3.17 | -2.98 | -13.94% |
| Price to Free Cash Flow TTM | 17.69 | 14.86 | 12.03 | 11.10 | -29.27% |
| Enterprise Value to EBITDA | 48.55 | 61.47 | 45.76 | 44.22 | -10.45% |
| Free Cash Flow Yield | 5.7% | 6.7% | 8.3% | 9.0% | 41.39% |
| Return on Equity | 12.3% | 12.0% | 11.3% | 10.3% | -18.34% |
| Total Debt | $1.04B | $1.04B | $1.04B | $1.08B | 5.08% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
